FinnHubSatellos Bioscience Inc. Announces Encouraging Functional Data from the 28-Day Phase 1B Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophyabout 1 month ago
FinnHubSatellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophyabout 1 month ago
FinnHubBloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrantsabout 1 month ago
FinnHubSatellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025about 1 month ago
CashuSatellos Bioscience Inc. Advances SAT-3247 for Promising Duchenne Muscular Dystrophy Treatment28 days ago
CashuSatellos Bioscience Inc. Boosts Investor Relations with $1.6M Warrant Exercise by Bloom Burton29 days ago